Market Research Report
Global Human Growth Hormone Market 2018-2022
|Published by||TechNavio (Infiniti Research Ltd.)||Product code||320559|
|Published||Content info||110 Pages
Delivery time: 1-2 business days
|Global Human Growth Hormone Market 2018-2022|
|Published: December 14, 2018||Content info: 110 Pages||
Increasing incidence and prevalence of growth hormone disorders due to the growth hormone deficiency is expected to drive the human growth hormone market over the forecast period. Moreover, various indications fall under the growth hormone disorders such as turner syndrome, growth hormone deficiency, acromegaly, Noonan syndrome, gigantism, and many more. Technavio's analysts have predicted that the human growth hormone market will register a CAGR of almost 4% by 2022.
Many leading companies such as Novo Nordisk, Merck, and Pfizer have a strong pipeline in their portfolio for treating various growth hormone disorders. All these factors are expected to drive the global human growth hormone market during the forecast period.
The poor patient adherence for human growth hormone due to uneasiness with growth hormone administration will impact the treatment adherence and results.
For the detailed list of factors that will drive and challenge the growth of the human growth hormone market during the 2018-2022, view our report.
The market appears to be fragmented and with the presence of several companies including Novo Nordisk and Pfizer the competitive environment is quite intense. Factors such as the strong pipeline of human growth hormone and the increasing incidence and prevalence of growth hormone disorders, will provide considerable growth opportunities to human growth hormone manufactures. Eli Lilly, F. Hoffmann-La Roche, Novo Nordisk, and Pfizer are some of the major companies covered in this report.